Research Paper Volume 12, Issue 14 pp 14556—14568
TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy
Figure 2. The association between TP53 mutation status and overall survival of NSCLC patients treated with immunotherapies. (A) Kaplan-Meier survival curve analysis shows overall survival of NSCLC patients with TP53 mutations (n=217) and wild-type TP53 (n=133) in the MSK-IMPACT NSCLC cohort. (B) Kaplan-Meier survival curve analysis shows the overall survival of NSCLC patients with wild-type TP53 (n=133), TP53 non-truncating mutations (n=150) and TP53 truncating mutations (n=67) in the MSK-IMPACT NSCLC cohort. (C) Kaplan-Meier survival curve analysis shows the progression free survival (PFS) of patients with TP53 truncating mutations (n=10) and wildtype TP53 (n=32) in the MSK-NSCLC cohort.